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A B S T R A C T
One of the most promising viral targets in current hepatitis B virus (HBV) drug development is the core protein
due to its multiple roles in the viral life cycle. Here we investigated the diﬀerences in the mode of action and
antiviral activity of representatives of six diﬀerent capsid assembly modiﬁer (CAM) scaﬀolds: three from the
well-characterized scaﬀolds heteroarylpyrimidine (HAP), sulfamoylbenzamide (SBA), and phenylpropenamide
(PPA), and three from novel scaﬀolds glyoxamide-pyrrolamide (GPA), pyrazolyl-thiazole (PT), and dibenzo-
thiazepin-2-one (DBT). The target activity and antiviral eﬃcacy of the diﬀerent CAMs were tested in biochemical
and cellular assays. Analytical size exclusion chromatography and transmission electron microscopy showed that
only the HAP compound induced formation of aberrant non-capsid structures (class II mode of action), while the
remaining CAMs did not aﬀect capsid gross morphology (class I mode of action). Intracellular lysates from the
HepAD38 cell line, inducibly replicating HBV, showed no reduction in the quantities of intracellular core protein
or capsid after treatment with SBA, PPA, GPA, PT, or DBT compounds; however HAP-treatment led to a profound
decrease in both. Additionally, immunoﬂuorescence staining of compound-treated HepAD38 cells showed that
all non-HAP CAMs led to a shift in the equilibrium of HBV core antigen (HBcAg) towards complete cytoplasmic
staining, while the HAP induced accumulation of HBcAg aggregates in the nucleus. Our study demonstrates that
the novel scaﬀolds GPA, PT, and DBT exhibit class I modes of action, alike SBA and PPA, whereas HAP remains
the only scaﬀold belonging to class II inhibitors.
1. Introduction
Although an eﬀective prophylactic vaccine against hepatitis B virus
(HBV) infection is available since the 1980s, around 257 million people
still suﬀer from chronic HBV infection worldwide. In 2015, an esti-
mated loss of 32 million disability-adjusted life years and 887,000
deaths was attributed to HBV infection, most notably due to the re-
sulting liver cirrhosis and hepatocellular carcinoma (World Health
Organization, 2017). Current treatments reduce viral load either by
inhibition of the viral reverse transcriptase via nucleoside/nucleotide
analogs or immunomodulation induced by pegylated interferon-alpha.
However, as these treatments do not cure the infection, patients require
long-term or lifelong therapy. Consequently, the major goal of current
anti-HBV drug discovery is to develop novel drugs with new modes of
action resulting in virus elimination or at the least a functional HBV
cure, i.e. sustained, undetectable hepatitis B surface antigen (HBsAg)
and HBV DNA in the serum with or without anti-HBs seroconversion
(Lok et al., 2017).
HBV is a small enveloped DNA virus with a 3.2 kB, partially double-
stranded, relaxed circular DNA (rcDNA) genome (Kay and Zoulim,
2007). Its chromatin-like viral minichromosome persists in the nucleus
of infected cells in the form of a covalently closed circular DNA
(cccDNA). Of the various potential drug targets including the 7 viral
proteins, cccDNA, and HBV entry itself, the core protein (Cp) is one of
the most promising targets.
The Cp (21 kDa) has two domains: an alpha-helix rich N-terminal
assembly domain composed of residues 1–149 (Cp149, ∼17 kDa), and
an arginine-rich C-terminal domain (CTD, ∼4 kDa) composed of the
remaining 34–36 residues (depending on the genotype). The Cp forms
homodimers with an interface composed of four helices, two from each
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monomer (Wynne et al., 1999). Due to the key role of the Cp at multiple
stages in the viral life cycle (Zlotnick et al., 2015; Zoulim, 2005), it is
postulated that capsid assembly modiﬁers (CAMs) may inhibit HBV
replication and combat persistence on at least four diﬀerent levels.
Firstly, CAMs may misdirect capsid assembly due to altered assembly
kinetics, thereby preventing production of infectious virions (Stray
et al., 2005). Secondly, the absence of properly assembled capsids and
encapsulated rcDNA genomes blocks the so-called recycling pathway
and interferes with the maintenance of the cccDNA pool. Thirdly, CAMs
may deplete the pool of free Cp that maintains the cccDNA in a tran-
scriptionally active state (Levrero et al., 2009). Lastly, depletion of the
free Cp might remove the block on transcription of interferons and
interferon-stimulated genes, leading to restoration of the host's innate
immune response (Gruﬀaz et al., 2013).
CAMs fall into two functional classes: class I CAMs, including the
sulfamoylbenzamides (SBAs) and phenylpropenamides (PPAs), induce
assembly of morphologically intact, but empty, capsids (Berke et al.,
2017; Zhou et al., 2017), while class II CAMs, including the hetero-
arylpyrimidines (HAPs), provoke the formation of aberrant high-order
structures (Berke et al., 2017; Liu et al., 2017; Zhou et al., 2017). In
recent years, several new chemical scaﬀolds showing CAM activity have
been identiﬁed using screening or rational design (Hartman and Kuduk,
2016; Mani et al., 2018; Turner et al., 2015; Vandyck et al., 2015; Wang
et al., 2015; Yang et al., 2016). Of those CAMs which have been
classiﬁed to date, only HAP belongs to class II. In this study, we ana-
lyzed three previously unclassiﬁed CAMs belonging to the chemical
classes of pyrazolyl-thiazole (PT), glyoxamide-pyrrolamide (GPA) and
dibenzo-thiazepin-2-one (DPT) (Fig. 1). To elucidate their modes of
action, the novel CAMs were tested in diﬀerent biochemical and cell-
based assays together with a representative each of the HAP, SBA and
PPA scaﬀolds. To our knowledge, this is the ﬁrst systematic compre-
hensive assessment in which representatives of six diﬀerent chemical
scaﬀolds of HBV-speciﬁc CAMs have been compared head-to-head in
the same assays.
2. Materials and methods
2.1. Compounds
The reference nucleoside inhibitor, entecavir (ETV), was purchased
from Selleck Chemicals (Munich, Germany). CAMs shown in Fig. 1 were
synthesized as described by Hartman and Flores (2013), Hartman and
Kuduk (2016), Perni et al. (2000), Turner et al. (2015), Vandyck et al.
(2015). The HAP compound tested, BAY 41–4109, was synthesized at
Bayer AG (Wuppertal, Germany) (Deres et al., 2003). All compounds
have at least 99% purity.
List of abbreviations
aSEC analytical size exclusion chromatography
AUC area under the curve
CAA biochemical capsid assembly assay
CAM capsid assembly modiﬁer
CC50 half maximal cytotoxic concentration
cccDNA covalently closed circular DNA
Cp core protein
Cp149 N-terminal domain of the Cp
Cp150 mutant Cp149
CTD C-terminal domain of the Cp
DBT dibenzo-thiazepin-2-one
EC50 half maximal eﬀective concentration in cellular assay
EM electron microscopy
FBS fetal bovine serum
GPA glyoxamide-pyrrolamide
HAP heteroarylpyrimidine
HBcAg HBV core antigen
HBsAg HBV surface antigen
HBV hepatitis B virus
HRP horse radish peroxidase
IC50 half maximal inhibitory concentration in biochemical
assay
NAGE native agarose gel electrophoresis
PBS phosphate buﬀered saline
PPA phenylpropenamide
PT pyrazolyl-thiazole
qPCR quantitative polymerase chain reaction
rcDNA relaxed circular DNA
SBA sulfamoylbenzamide
Fig. 1. Chemical structures of the diﬀerent capsid assembly modiﬁers used (from top left to bottom right): heteroarylpyrimidine (HAP), sulfamoylbenzamide
(SBA), phenylpropenamide (PPA), pyrazolyl-thiazole (PT), glyoxamide-pyrrolamide (GPA), and dibenzo-thiazepin-2-one (DBT).
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2.2. HBV Cp puriﬁcation
The recombinant Cp assembly domain used in this study has an
additional C-terminal cysteine and has all its native cysteines replaced
with alanine (Cp150) (Zlotnick et al., 2007). Cp150 was expressed in
Escherichia coli Rosetta2 (DE3). After extraction using the Qproteome
Bacterial Protein Prep Kit (Qiagen) the proteins were precipitated with
ammonium sulfate to 40% saturation, and dissolved in Buﬀer A
(100mM Tris, pH 7.5, 100mM NaCl, 2 mM DTT). The assembled capsid
material was puriﬁed using a CaptoCore 700 HiTrap aﬃnity column
(GE Healthcare) equilibrated with Buﬀer A and mounted on an ÄKTA
Explorer 10 (GE Healthcare). The resulting ﬂow through was then
dialyzed into Buﬀer N (50mM sodium bicarbonate, 5 mM DTT, pH 9.6).
The capsids were then disassembled into dimers using 3M urea, and
isolated using a Sephacryl S-300 HR XK 50/60 size exclusion column
(GE Healthcare) equilibrated with Buﬀer N. The dimer peak was en-
riched using an Amicon Stirred Ultraﬁltration Cell (Millipore), and
dialyzed into HEPES buﬀer (50mM HEPES, pH 7.5, 5 mM DTT). To
conﬁrm the assembly activity of the isolated dimers, a second round of
assembly with 0.5 M NaCl and disassembly with 3M urea was per-
formed. Assembled capsids and assembly-active dimers were isolated
using the same aﬃnity and size exclusion columns, respectively.
2.3. Biochemical capsid assembly assay (CAA)
The assay was performed according to Zlotnick et al. (2007), with
some modiﬁcations. Brieﬂy, Cp150 was ﬂuorescently labelled at its C-
terminus with BODIPY-FL (maleimide) dye (Molecular Probes). Then,
1.5 μM of the labelled Cp150 was incubated for 6min with various
concentrations of test compound in a reaction buﬀer containing 50mM
HEPES, pH 7.5, 150mM NaCl and 1% DMSO. Fluorescence was mea-
sured on a ClarioStar plate reader (BMG Labtech). In the dimeric state,
the ﬂuorescence signal from the dye is high; this is then quenched upon
capsid assembly. Assembly was quantiﬁed as in Equation (1), where the
negative control contains only protein in 50mM HEPES, pH 7.5.
=
−
×Assembly Sample Negative control
Negative control
% 100%RFU RFU
RFU (1)
2.4. Analytical size exclusion chromatography (aSEC)
Five micromolar Cp150 was incubated in 60mM BES, pH 6.8,
150mM NaCl and 1% DMSO and with various concentrations of test
compound at 25 °C for 2 h. Afterwards, samples were separated on a
Superose6 Increase 10/300 size-exclusion column (GE Healthcare)
mounted on an ÄKTA Explorer 10 using the same buﬀer. The eﬀect of
the compound on capsid assembly was derived as the ratio of the area
under the curve (AUC) of the capsid peak to the AUC of the dimer peak.
2.5. Electron microscopy (EM)
Samples were incubated as described in Section 2.4, but with test
compounds at 50-fold IC50 concentration. The assembly products were
analyzed at the Electron Microscopy Core Facility in Heidelberg. Sam-
ples were adsorbed onto 300-mesh carbon-coated and glow-discharged
grids, negatively stained with 3% uranyl acetate in water, and viewed
under a transmission electron microscope (Jeol JEM-1400) at 80kV.
Images were taken using a TEMCAM F416 camera (TVIPS) and ana-
lyzed with ImageJ (National Institutes of Health, ver. 1.51j8).
2.6. HBV antiviral assay
The HepAD38 cell line, a tetracycline-inducible HepG2 cell line
stably transfected with HBV (Ladner et al., 1997), was obtained from
Prof. Christoph Seeger (Fox Chase Cancer Center, Philadelphia, PA). In
96-well plates, 80,000 HepAD38 cells/well were seeded without tetra-
cycline, and treated with serial half-log dilutions of test compounds for
6 days. Cell culture supernatants were collected at the end, and HBV
DNA was extracted using the MagNAPure Viral Nucleic Acid Universal
Small Volume kit (Roche). DNA was then measured using quantitative
PCR (qPCR) with HBx-speciﬁc primers and probes, and the LightCycler
480 Probes Master kit (Roche). Additionally, identically treated non-
HBV expressing HepAD38 cells (i.e., cultured with tetracycline) were
used to determine the cytotoxicity of the test compounds. For this,
PrestoBlue (Invitrogen) was added on day 6 and the half maximal cy-
totoxic concentration (CC50) was determined according to the manu-
facturer's protocol.
2.7. HBV particle gel assay
Intracellular HBV particles were assayed as described by Campagna
et al. (2013) and Guo et al. (2006), with some modiﬁcations. Brieﬂy, 6-
well plates were seeded with 1×106 HepAD38 cells/well without
tetracycline, and treated with test compounds at 10-fold the half
maximal eﬀective concentration (EC50) for 6 days. At the end of
treatment, cells were lysed with a buﬀer containing 10mM Tris, pH 7.5,
100mM NaCl, 1 mM EDTA, 0.1% NP-40. Cell debris was pelleted at
5000 g for 10min. The resulting supernatants were separated on a
4–12% NuPAGE Bis-Tris gel (Invitrogen), and a 1% native agarose gel.
The samples were then transferred onto nitrocellulose membranes, and
probed with antibodies against HBV core antigen (HBcAg) (Dako
B0586) and β-actin (Sigma A1978). Bound antibodies were detected
with horse radish peroxidase (HRP)-conjugated antibodies against
rabbit (Abcam ab6721) or mouse (Abcam ab6789), and visualized with
ECL Prime Western Blotting detection reagent (GE Healthcare).
2.8. Immunoﬂuorescence assay
Sterile cover slips in 6-well plates were seeded at a density of
1× 105 HepAD38 cells/well. Cells were cultured without tetracycline
for 6 days with 10-fold EC50 of test compounds. The cells were ﬁxed
Table 1
Anti-HBV activity and cytotoxicity of six diﬀerent CAMs and ETV tested in
HepAD38 cells.
Compounds μm EC50 (mean ± SD) μm CC50 (mean ± SD)
HAP 0.068 ± 0.029 >32
SBA 0.22 ± 0.095 18 ± 3.4
PPA 0.20 ± 0.33 > 32
GPA 0.0014 ± 0.00089 >100
PT 0.020 ± 0.0099 >32
DBT 0.14 ± 0.076 >32
ETV 0.00057 ± 0.00050 >0.18
*All compounds were tested at least thrice.
Table 2
Biochemical target activity of six diﬀerent CAMs tested on Cp150 in vitro.
Compounds CAA aSEC
μm IC50 (mean ± SD) μm IC50 (mean ± SD)
HAP 0.34 ± 0.17 0.9 ± 0.1
SBA 1.2 ± 0.45 1.2 ± 0.2
PPA 0.61 ± 0.23 1.3 ± 0.2
GPA 0.60 ± 0.099 1.3 ± 0.4
PT 1.4 ± 0.46 1.5 ± 0.1
DBT 0.70 ± 0.27 1.4 ± 0.2
*CAA = capsid assembly assay, aSEC = analytical size exclusion chromato-
graphy, HAP = heteroarylpyrimidine, SBA = sulfamoylbenzamide,
PPA = phenylpropenamide, GPA = glyoxamide-pyrrolamide, PT = pyrazolyl-
thiazole, DBT = dibenzo-thiazepin-2-one.
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with 4% paraformaldehyde in phosphate buﬀered saline (PBS), and
permeabilized with 0.2% Triton X-100 in PBS. The cells were then
blocked with 5% fetal bovine serum in PBS (FBS/PBS). HBcAg was
detected with anti-HBc (Abcam ab115992) and anti-rabbit-Alexa 488
antibodies (Invitrogen A-11034) in 5% FBS/PBS. The samples were
then mounted using the VECTASHIELD hardset antifade medium with
DAPI (Vector Laboratories), and viewed under an inverted ﬂuorescence
microscope (Leitz DMRB). Images were taken with the SpotFlex camera
and SpotAdvanced 4.6 software (Visitron Systems). Selected samples
were also examined using a point-scanning confocal microscope (Leica
SP8) with ∼0.3 μm optical sections. Images were analyzed using
ImageJ (National Institutes of Health, ver. 1.51j8) or Fiji (ver. 2.0.0-rc-
65/1.52a).
2.9. Subcellular fraction analysis
Cells were cultured and treated in the same manner as in Section
2.7. Afterwards, cells were washed with PBS and collected from the
plate via trypsinization. The cell pellet was then lysed using a hypotonic
buﬀer (10mM Tris, pH 7.5, 10mM KCl, 0.1mM EDTA, 1mM DTT,
cOmplete EDTA-free protease cocktail (Roche), 0.5% NP-40). Samples
were brieﬂy vortexed, and the cytoplasmic fraction was separated at
12,000 g for 10min. The nuclear pellet was then washed three times
with the hypotonic buﬀer without NP-40. Afterwards, the pellet was
then resuspended in nuclear extraction buﬀer (20mM Tris, pH 7.5,
400mM NaCl, 1 mM EDTA, 1mM DTT, cOmplete EDTA-free protease
cocktail, 25% glycerol) with periodic mixing. Samples were brieﬂy
vortexed, and the nuclear fraction was isolated at 12,000 g for 15min.
The nuclear and cytoplasmic fractions were run on a 4–12% NuPAGE
Bis-Tris gel, and transferred onto nitrocellulose membranes. Mem-
branes were probed with antibodies against HBcAg (Dako B0586), α-
tubulin (Abcam ab4074) and lamin B1 (Abcam ab16048), followed by a
secondary anti-rabbit HRP antibody (Abcam ab6721). Bound antibodies
were visualized with ECL Prime Western Blotting detection reagent.
2.10. IC50 and EC50 calculations
The half maximal inhibitory concentration (IC50) values for the
biochemical assays and EC50 values for the cell-based assays were cal-
culated from dose-response curves using non-linear regression analysis
of GraphPad Prism (GraphPad, ver. 6.03).
3. Results and discussion
3.1. Antiviral activity of diﬀerent CAMs in HepAD38 cells
The antiviral activities of the six diﬀerent CAMs were analyzed with
the inducible, stably transfected HBV cell line HepAD38. After six days
of HBV induction (without tetracycline) in the presence of diﬀerent
concentrations of each CAM, extracellular DNA from cell supernatants
was quantiﬁed using qPCR. Cytotoxicity of the test compounds was also
determined after the same incubation period using the same cell line in
the presence of tetracycline to suppress HBV replication. The resulting
cell viability was quantiﬁed with PrestoBlue. As expected for CAMs, all
six diﬀerent compounds analyzed in this study inhibited HBV DNA
replication in a dose-dependent manner, with the most active, the GPA
Fig. 2. Analytical size exclusion chromatography of six diﬀerent CAMs in
vitro. Cp150 was incubated with 150mM NaCl and 10 μM compound at 25 °C
for 2 h prior to separation on a Superose6 Increase column. Two distinct peaks
were observed, with the capsid peak (at∼ 9mL) eluting before the dimer peak
(at∼ 18mL). The samples incubated with the SBA and PPA compounds showed
no shift in capsid peak, while those incubated with GPA, PT, and DBT com-
pounds showed a slight shift. The sample incubated with the HAP compound
showed the greatest shift of the capsid peak towards larger structures.
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representative with an EC50 of 1.4 nM, to the least active, the SBA re-
presentative with an EC50 of 220 nM (Table 1). In comparison, the
positive control ETV showed an EC50 of 0.6 nM, in line with published
data (Berke et al., 2017). The SBA compound showed the lowest CC50
among the CAMs (18 μM), and a selectivity index below 100.
3.2. Eﬀect of diﬀerent CAMs on HBV capsid formation
By deﬁnition, a compound with CAM activity accelerates the HBV
capsid assembly reaction in a dose-dependent manner (Stray et al.,
2005; Zlotnick et al., 2007). Therefore, we ﬁrst analyzed the diﬀerent
CAMs in the CAA by monitoring the ﬂuorescence quenching of BODIPY-
C-terminally labelled Cp150 in the presence of diﬀerent CAM con-
centrations over time. As listed in Table 2, all six CAMs accelerated
capsid formation compared to the untreated control with IC50 values
varying between 0.34 and 1.4 μM. Using this ﬂuorescence quenching
assay, HAP showed the highest activity (0.34 μM), whereas SBA and PT
showed the lowest activity (1.2 μM and 1.4 μM, respectively).
In an alternative method, we calculated the IC50 values from the
ratio of the capsid to the dimer peak following aSEC at various CAM
concentrations. As shown in Fig. 2, at physiological sodium chloride
concentration, the unlabelled Cp150 protein mainly eluted at high re-
tention volume of more than 16mL, which corresponds to the Cp dimer,
whereas at a high sodium chloride concentration of 1M, the Cp eluted
at a lower retention volume (mainly below 12mL), which corresponds
to the high molecular weight capsid. IC50 values calculated from aSEC
analysis ranged from 0.9 μM to 1.5 μM (Table 2). These values are more
closely grouped than those obtained from the CAA. While IC50 values
can be inﬂuenced by the assay conditions, it is important to note that
the signal obtained in the CAA to distinguish between dimer and capsid
molecules results from the quenching of the ﬂuorescent dye upon
capsid assembly. The apparently superior activity of HAP in this assay
may result from to its ability to induce formation of aberrant, high-
order structures with potentially greater quenching eﬀects.
Additionally, we looked at the retention volume of the capsid peak
to get an overall view of its size. As previously described (Berke et al.,
2017), only HAP treatment led to a shift of the corresponding capsid
peak to lower retention volumes; no shift was observed for the samples
treated with the SBA and PPA, in addition to the novel scaﬀolds GPA,
PT or DBT (Fig. 2). By progressively increasing the concentration of the
HAP compound up to a maximum of 50 μM, we were able to shift the
capsid peak to even lower retention volumes such that the Superose6
column was no longer able to separate the capsid peak (data not
shown). Our aSEC data indicate that only the HAP compound exhibits a
class II mode of action, whereas results for the SBA, PPA, GPA, PT and
DBT compounds were consistent with class I.
3.3. Eﬀect of diﬀerent CAMs on the morphology of HBV capsids
To further investigate the eﬀect of diﬀerent CAMs on the mor-
phology of HBV capsids, we performed EM analyses with Cp150 in
presence or absence of the CAMs. Consistent with previous studies
(Berke et al., 2017; Zhou et al., 2017), no signiﬁcant morphological
changes of capsid structures were induced by class I SBA and PPA
compounds, while aberrant structures, with an increased tendency to
aggregate were formed after incubation with the class II HAP com-
pound. In this study, no signiﬁcant changes were also apparent in
capsid morphology in samples treated with GPA or DBT (Fig. 3).
However, in PT-treated samples, a minor increase in number of ab-
normally shaped or sized capsids was apparent. These data were
Fig. 3. Electron microscopy analysis of core protein treated with six diﬀerent CAMs in vitro. Cp150 was incubated with 150mM NaCl and 50-fold aSEC IC50 of
the compound speciﬁed on the bottom of each panel for 1 h at room temperature prior to negative staining. In addition, a positive control of Cp150 incubated with
1M NaCl was prepared as a reference for normal capsid morphology (upper left). The HAP-treated sample exhibited a distinct morphology with larger structures that
tended to aggregate. Cp150 treated with the other CAMs produced morphologically intact capsids.
Fig. 4. Intracellular capsid and core protein in HepAD38 cells treated with
diﬀerent CAMs. Cells were cultured with 10-fold the EC50 of the respective test
compound for 6 days. Proteins in cell lysates were separated by SDS-PAGE (a)
and a native agarose gel (b). The negative control (−) shown is lysate from
DMSO-treated HepAD38 cells cultured with tetracycline (i.e., with suppressed
HBV replication), while the positive control (+) shown is lysate from DMSO-
treated HepAD38 cells cultured without tetracycline, allowing HBV replication.
Cp and capsids were probed with an anti-HBc antibody (Dako), and β-actin was
used as a loading control. Note that in both native and denatured gels the Cp
and capsid signal was reduced in HAP-treated cells.
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consistent with what we observed in the aSEC analysis, wherein HAP-
treated samples had the greatest shift in capsid peak retention volume
towards larger structures and aggregates (Fig. 2).
3.4. Eﬀect of diﬀerent CAMs on intracellular core protein concentration
and capsid formation in vitro
It has been previously reported that treatment of cells with class I
CAM molecules, e.g. the SBA scaﬀold, does not alter amounts of in-
tracellular Cp and capsid particles, whereas compounds with the HAP
scaﬀold (class II) cause a strong reduction in both intracellular Cp and
capsids (Mani et al., 2018; Zhou et al., 2017). To examine the possible
diﬀerences in the mode of action of the six diﬀerent CAMs side-by-side,
the quantities of intracellular Cp and HBV capsids in compound-treated
HepAD38 cells were analyzed using Western blot and particle gel assay.
It is important to note that compared to biochemical assays, additional
factors come into play in cell culture assays, such as cell permeability,
drug solubility, target aﬃnity and binding. The intracellular environ-
ment is more complex than that of a simple biochemical assay. In order
to reﬂect the large diﬀerences in the antiviral activities of the diﬀerent
Fig. 5. Immunoﬂuorescence assay of HepAD38 cells treated with diﬀerent CAMs. Cells were cultured without tetracycline to induce HBV replication and with
10-fold the EC50 of the respective test compound for 6 days. HBcAg (green) was visualized via indirect immunoﬂuorescence staining using an inverted ﬂuorescence
microscope; nuclear DNA was counterstained with DAPI (blue). The merged images of the two stains are depicted in the bottom row. In DMSO-treated control cells,
HBcAg is located in both the nucleus and cytoplasm. In HAP-treated cells Cp displayed punctuated aggregates, while cells treated with all the other CAMs showed
almost complete cytoplasmic staining of Cp.
Fig. 6. Subcellular analysis of CAM-treated
HepAD38 cells. (a) Immunoﬂuorescence assay samples
were viewed with a confocal microscope to visualize
nuclear localization of punctate HBcAg (green) ag-
gregates in HAP-treated cells; nuclear DNA was counter-
stained with DAPI (blue). Representative 3D optical sec-
tions (xy and orthogonal views xz and yz) are shown. (b)
Cytoplasmic and nuclear fractions of HAP-treated
HepAD38 cells were separated using standard fractiona-
tion methods and analyzed by Western blot using an anti-
HBc antibody (Dako). No Cp was detected in the cyto-
plasmic fraction of the HAP-treated sample compared to
the positive control (+) of DMSO-treated HepAD38 cells
cultured without tetracycline. However, for the nuclear
fraction, Cp was detected in HAP-treated cells. Lamin B1
and α-tubulin were used as nuclear and cytoplasmic
loading controls, respectively. Negative control (−) used
was DMSO-treated HepAD38 cells cultured with tetra-
cycline.
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CAM scaﬀold representatives (Table 1), multiples of EC50 rather than
equal absolute concentrations were used in the following in vitro cell
culture assays. As shown in Fig. 4, treatment of the cells with SBA, GPA,
PT or DBT compounds at 10-fold EC50 did not alter the amounts of
intracellular Cp or capsids, as compared to the DMSO-treated control,
while PPA showed slightly elevated levels of capsid protein. In contrast,
the HAP compound caused a strong reduction in both intracellular Cp
and capsid formation (Fig. 4). A study by Deres et al. (2003) has shown
that this reduction is mediated by proteasome degradation. Based on
this comparison of the intracellular amounts of Cp and capsid particles,
we could conﬁrm the hypothesis that all non-HAP CAMs tested in this
study share a class I mode of action.
3.5. Eﬀect of diﬀerent CAMs on the subcellular localization of the HBV core
antigen
We used immunoﬂuorescence microscopy to investigate the eﬀects
of CAM treatment on intracellular Cp and capsid particle localization.
As shown in Fig. 5, after six days of culture, the signal for HBcAg in
DMSO-treated control cells could be found distributed throughout the
cell and both in the cytoplasm and the nucleus. Interestingly, all non-
HAP CAMs induced a completely diﬀerent phenotype. In SBA, PPA,
GPA, PT or DBT compound-treated samples, the signal for HBcAg in
HepAD38 cells was located exclusively in the cytoplasm with virtually
no apparent nuclear staining. In addition, the amount of cytoplasmic
HBcAg seemed to be increased in cells incubated with these CAMs
compared to the DMSO-treated control cells (Fig. 5). On the other hand,
HAP-treated cells showed punctate Cp aggregates, which under con-
focal microscopy were observed within the nucleus (Fig. 6a). To further
conﬁrm this subcellular localization, cytoplasmic and nuclear fractions
of the lysate of HAP-treated cells were analyzed using Western blot
(Fig. 6b). Strong reduction of the Cp was observed in the cytoplasmic
fraction of the HAP-treated sample. However, in the nuclear fraction,
Cp was detected in the HAP-treated sample. In addition to the expected
full length Cp band, two lower bands, possibly degraded or truncated
Cp products, were observed.
4. Conclusion
The HBV Cp and its assembly into capsids have no known human
homologs, making Cp an attractive antiviral target. In addition, due to
their alternative modes of action, CAMs are also active against nu-
cleoside/nucleotide analog-resistant mutants (Billioud et al., 2011).
Currently, there are several CAMs under clinical development. Studies
have shown that although class I and class II CAMs bind to the same
pocket on the dimer-dimer interface of the protein, there are diﬀerences
in the eﬀect exerted on the overall capsid structure, leading to either
intact (class I CAMs) or aberrant structures (class II CAMs)
(Venkatakrishnan et al., 2016; Zhou et al., 2017). Katen et al. (2013)
have proposed that the ability of PPA compounds to induce formation
of morphologically intact capsids is due to changes in the tertiary
structure of the Cp dimer that permit compensatory changes in the
quaternary structure while HAPs do not permit such changes.
The intention of this study was to look at three, so far unclassiﬁed,
CAM scaﬀolds, the GPA, PT, and DBT, and compare these head-to-head
with the well-characterized SBA and PPA scaﬀolds as models for the
class I mode of action, and HAP scaﬀold for the class II. Our results
suggest that along with the SBA and PPA scaﬀolds, GPA, PT and DBT
scaﬀolds also exhibit class I modes of action, while the HAP scaﬀold
remains the only identiﬁed representative of the class II to date. In
addition, we could demonstrate that aside from inducing the assembly
of morphologically intact, but empty capsids, class I CAM molecules
induce an exclusive cytoplasmic accumulation of Cp. We hypothesize
that this could cause a Cp depletion in the nucleus, which might aﬀect
some other steps of the viral life cycle such as maintenance of active
cccDNA transcription since Cp binding to the minichromosome may
alter nucleosome spacing (Bock et al., 2001), and in particular, aﬀect
histone acetylation and DNA methylation by interacting with CpG is-
land 2 on the minichromosome (Guo et al., 2011). Another study has
shown that Cp in the nucleus may inhibit dsRNA-mediated interferon
response either by directly binding to the promoter regions of inter-
feron stimulated genes or recruitment of epigenome-modifying en-
zymes (Gruﬀaz et al., 2013).
Interestingly, we found that HAP compound treatment, on the other
hand, induced an aggregation of Cp in the nuclei of HBV-producing
cells. Very recently, Huber et al. (2018) have shown that these HAP-
induced nuclear Cp aggregates are associated with promyelocytic leu-
kemia nuclear bodies, which may lead to diﬀerent pleiotropic eﬀects
such as induction of apoptosis or cellular senescence, which would not
be the case with class I CAMs. Further studies are needed to determine
whether these diﬀerences may impact the potential for CAMs to achieve
HBV cure in the clinic.
Declaration of interest
A.C., K.S., A.B., and A.U. are employees of AiCuris Anti-infective
Cures GmbH.
Acknowledgments
The authors gratefully acknowledge the guidance of Dr. Marina May
in the protein puriﬁcation, and the excellent technical assistance of
Wiebke Schultze, Ilva Leckebusch, Uta Haselmann and the Electron
Microscopy Core Facility of the Heidelberg University. We also thank
Dr. Rob Saunders, biomed context, for his help editing the manuscript.
This project was supported by a research grant from the European
Union's Horizon 2020 research and innovation program under the
Marie Sklodowska-Curie grant agreement No. 642434.
References
Berke, J.M., Dehertogh, P., Vergauwen, K., Van Damme, E., Mostmans, W., Vandyck, K.,
Pauwels, F., 2017. Capsid assembly modulators have a dual mechanism of action in
primary human hepatocytes infected with hepatitis B virus. Antimicrob. Agents
Chemother. 61 e00560-00517.
Billioud, G., Pichoud, C., Puerstinger, G., Neyts, J., Zoulim, F., 2011. The main hepatitis B
virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-
nucleoside inhibitors of HBV replication. Antivir. Res. 92, 271–276.
Bock, C.T., Schwinn, S., Locarnini, S., Fyfe, J., Manns, M.P., Trautwein, C., Zentgraf, H.,
2001. Structural organization of the hepatitis B virus minichromosome. J. Mol. Biol.
307, 183–196.
Campagna, M.R., Liu, F., Mao, R., Mills, C., Cai, D., Guo, F., Zhao, X., Ye, H., Cuconati, A.,
Guo, H., Chang, J., Xu, X., Block, T.M., Guo, J.T., 2013. Sulfamoylbenzamide deri-
vatives inhibit the assembly of hepatitis B virus nucleocapsids. J. Virol. 87,
6931–6942.
Deres, K., Schroder, C.H., Paessens, A., Goldmann, S., Hacker, H.J., Weber, O., Kramer, T.,
Niewohner, U., Pleiss, U., Stoltefuss, J., Graef, E., Koletzki, D., Masantschek, R.N.,
Reimann, A., Jaeger, R., Gross, R., Beckermann, B., Schlemmer, K.H., Haebich, D.,
Rubsamen-Waigmann, H., 2003. Inhibition of hepatitis B virus replication by drug-
induced depletion of nucleocapsids. Science 299, 893–896.
Gruﬀaz, M., Testoni, B., Luangsay, S., Ait-Goughoulte, M., Petit, M.A., Ma, H., Klumpp, K.,
Javanbakht, H., Durantel, D., Zoulim, F., 2013. 378 hepatitis B core (hbc) protein is a
key and very early negative regulator of the interferon response. J. Hepatol. 58,
S155–S156.
Guo, H., Aldrich, C.E., Saputelli, J., Xu, C., Mason, W.S., 2006. The insertion domain of
the duck hepatitis B virus core protein plays a role in nucleocapsid assembly. Virology
353, 443–450.
Guo, Y.-H., Li, Y.-N., Zhao, J.-R., Zhang, J., Yan, Z., 2011. HBc binds to the CpG islands of
HBV cccDNA and promotes an epigenetic permissive state. Epigenetics 6, 720–726.
Hartman, G.D., Flores, O.A., inventors; Novira Therapeutics, Inc., assignee. Hepatitis B
antiviral agents. World patent WO 2013/096744 A1. 2013 June 27.
Hartman, G.D., Kuduk, S., inventors; Novira Therapeutics, Inc., assignee. Derivatives and
methods of treating Hepatitis B infections. World patent WO 2016/109689 A2. 2016
July 7.
Huber, A.D., Wolf, J.J., Liu, D., Gres, A.T., Tang, J., Boschert, K.N., Puray-Chavez, M.N.,
Pineda, D.L., Laughlin, T.G., Coonrod, E.M., Yang, Q., Ji, J., Kirby, K.A., Wang, Z.,
Saraﬁanos, S.G., 2018. The heteroaryldihydropyrimidine bay 38-7690 induces he-
patitis B virus core protein aggregates associated with promyelocytic leukemia nu-
clear bodies in infected cells. mSphere 3.
Katen, S.P., Tan, Z., Chirapu, S.R., Finn, M.G., Zlotnick, A., 2013. Assembly-directed
antivirals diﬀerentially bind quasiequivalent pockets to modify hepatitis B virus
A. Corcuera et al. Antiviral Research 158 (2018) 135–142
141
capsid tertiary and quaternary structure. Structure 21, 1406–1416.
Kay, A., Zoulim, F., 2007. Hepatitis B virus genetic variability and evolution. Virus Res.
127, 164–176.
Ladner, S.K., Otto, M.J., Barker, C.S., Zaifert, K., Wang, G.H., Guo, J.T., Seeger, C., King,
R.W., 1997. Inducible expression of human hepatitis B virus (HBV) in stably trans-
fected hepatoblastoma cells: a novel system for screening potential inhibitors of HBV
replication. Antimicrob. Agents Chemother. 41, 1715–1720.
Levrero, M., Pollicino, T., Petersen, J., Belloni, L., Raimondo, G., Dandri, M., 2009.
Control of cccDNA function in hepatitis B virus infection. J. Hepatol. 51, 581–592.
Liu, C., Fan, G., Wang, Z., Chen, H.S., Yin, C.C., 2017. Allosteric conformational changes
of human HBV core protein transform its assembly. Sci. Rep. 7, 1404.
Lok, A.S., Zoulim, F., Dusheiko, G., Ghany, M.G., 2017. Hepatitis B cure: from discovery
to regulatory approval. Hepatology 66, 1296–1313.
Mani, N., Cole, A.G., Phelps, J.R., Ardzinski, A., Cobarrubias, K.D., Cuconati, A., Dorsey,
B.D., Evangelista, E., Fan, K., Guo, F., Guo, H., Guo, J.T., Harasym, T.O., Kadhim, S.,
Kultgen, S.G., Lee, A.C.H., Li, A.H.L., Long, Q., Majeski, S.A., Mao, R., McClintock,
K.D., Reid, S.P., Rijnbrand, R., Snead, N.M., Micolochick Steuer, H.M., Stever, K.,
Tang, S., Wang, X., Zhao, Q., Soﬁa, M.J., 2018. Preclinical proﬁle of AB-423, an
inhibitor of Hepatitis B virus pgRNA encapsidation. Antimicrob. Agents Chemother.
62 (6).
Perni, R.B., Conway, S.C., Ladner, S.K., Zaifert, K., Otto, M.J., King, R.W., 2000.
Phenylpropenamide derivatives as inhibitors of hepatits B virus replication. Bioorg.
Med. Chem. Lett 10, 2687–2690.
Stray, S.J., Bourne, C.R., Punna, S., Lewis, W.G., Finn, M.G., Zlotnick, A., 2005. A het-
eroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid as-
sembly. Proc. Natl. Acad. Sci. U. S. A. 102, 8138–8143.
Turner, W.W., Arnold, L.D., Maag, H., Zlotnick, A., inventors; Indiana University Research
and Technology Corporation; Assembly Biosciences Inc., assignee. Hepatitis B core
protein allosteric modulators. World patent WO 2015/138895 A1. 2015
September 17.
Vandyck, K., Kesteleyn, B., Rudolf, Romanie, Pieters, S., Maria, Aloysius, Rombouts, G.,
Verschueren, W., Gaston, Raboisson, P., Jean-Marie, Bernard, inventors; Janssen R&D
Ireland, assignee. Glyoxamide substituted pyrrolamide derivatives and the use
thereof as medicaments for the treatment of Hepatitis B. World patent WO 2015/
011281 A1. 2015 January 29.
Venkatakrishnan, B., Katen, S.P., Francis, S., Chirapu, S., Finn, M.G., Zlotnick, A., 2016.
Hepatitis B virus capsids have diverse structural responses to small-molecule ligands
bound to the heteroaryldihydropyrimidine pocket. J. Virol. 90, 3994–4004.
Wang, Y.J., Lu, D., Xu, Y.B., Xing, W.Q., Tong, X.K., Wang, G.F., Feng, C.L., He, P.L.,
Yang, L., Tang, W., Hu, Y.H., Zuo, J.P., 2015. A novel pyridazinone derivative inhibits
hepatitis B virus replication by inducing genome-free capsid formation. Antimicrob.
Agents Chemother. 59, 7061–7072.
World Health Organization, 2017. Hepatitis B: Fact Sheet No 204. at. http://www.who.
int/mediacentre/factsheets/fs204/en/, Accessed date: 23 March 2018.
Wynne, S.A., Crowther, R.A., Leslie, A.G.W., 1999. The crystal structure of the human
hepatitis B virus capsid. Mol. Cell 3, 771–780.
Yang, L., Wang, Y.J., Chen, H.J., Shi, L.P., Tong, X.K., Zhang, Y.M., Wang, G.F., Wang,
W.L., Feng, C.L., He, P.L., Xu, Y.B., Lu, M.J., Tang, W., Nan, F.J., Zuo, J.P., 2016.
Eﬀect of a hepatitis B virus inhibitor, NZ-4, on capsid formation. Antivir. Res. 125,
25–33.
Zhou, Z., Hu, T., Zhou, X., Wildum, S., Garcia-Alcalde, F., Xu, Z., Wu, D., Mao, Y., Tian, X.,
Zhou, Y., Shen, F., Zhang, Z., Tang, G., Najera, I., Yang, G., Shen, H.C., Young, J.A.,
Qin, N., 2017. Heteroaryldihydropyrimidine (HAP) and sulfamoylbenzamide (SBA)
inhibit hepatitis B virus replication by diﬀerent molecular mechanisms. Sci. Rep. 7,
42374.
Zlotnick, A., Lee, A., Bourne, C.R., Johnson, J.M., Domanico, P.L., Stray, S.J., 2007. In
vitro screening for molecules that aﬀect virus capsid assembly (and other protein
association reactions). Nat. Protoc. 2, 490–498.
Zlotnick, A., Venkatakrishnan, B., Tan, Z., Lewellyn, E., Turner, W., Francis, S., 2015.
Core protein: a pleiotropic keystone in the HBV lifecycle. Antivir. Res. 121, 82–93.
Zoulim, F., 2005. New insight on hepatitis B virus persistence from the study of in-
trahepatic viral cccDNA. J. Hepatol. 42, 302–308.
A. Corcuera et al. Antiviral Research 158 (2018) 135–142
142
